

Index

Note: References to tables are given in bold type; references to figures are given in italic type.

- Abbott library **41**
Acetylcholinesterase (AChE) 186–90
Adipocyte fatty acid binding protein **83**
Alanine *202*
Alzheimer's disease **261**
Ames test **215**
Applications, fragments 10–11
Assay assessment 19–20
Assay techniques, fragment screening **43**
Astex library **41**
AstraZeneca library **41**
ATLAS (Astex Therapeutics Library of Available Substances) **230**
ATP synthase **145**
Available Chemical Directory **86**
- BACE
 binding affinities 264–5
 inhibitor 229–31, 232–4, 261
Bacillus cereus **182**
Bacterial markers **144**
BcII **182**
Bcl-xL 114–15
 β -secretase 261–76
Binding assays 23–4
Binding energy **7**
Bioactivity, validation **53**
Biochemical and biophysical screening **20**,
 22–5, 69–70
Biovitrum **83**
Breakaway tethering 250–1
Bruker HyStar software **142**
BVT.1960 **85, 86, 87**
CA II-bound ligands **182**
Capture, *see* fragment capture
Carbionic anhydrase *179, 249*
 screening via ESI-FTMS 178–83
Caspase-3 *249, 250*
Catabolism 29–30
Catalysis, and fragment screening 48–9
CDK2 **109, 124**
ChemBridge database 224, 227–8
Chemical genomics **18**
Chemical shift 112–13
Chemical space **42**
Chromatography, and DCL screening **167**
Click chemistry 48–9, *191*
 compound identification 167–9
 and mass spectrometry 186–90
 microfluidics 190–3, *191*
 overview 164–5
Colicin E1 **145**
Combinatorial chemistry, overview 161–2
Common substructure, definition 206–7
Competition experiments, NMR **82**
Compositional SAR **26**
Compound assessment 20–2
Comprehensive Medicinal Chemistry (CMC)
 database 51, 209–12
Computational chemistry
 focused sets **46**
 fragmentation methods 200–9
 modelling 27–30
 overview **199**

- Computational chemistry (*Continued*)
 subgraph mining 201–7
 substructure mining 207–9
 TINS 137
 virtual fragment screening 228–9
 BACE-1 229–31
- Covalent capture 246–7, 246
 using imines 252–3
- Cysteines 254
- Databases
 identifying biological activity 214–15
 multiple 212–14
 predictive models 215–18
 single databases 209–12
 survey 224–8
- Data mining, subgraph mining 201–7
- DCC, *see* direct combinatorial chemistry
- Derwent World Drug Index 47
- Dihydroisocytosines 272–5
- DIOS mass spectrometry 186–7
- Direct combinatorial chemistry
 compound identification 167
 reversible reactions 162–4
in situ 177–86
- Disulfide bonds, irreversible 254–5
- Diversity algorithms 45–6
- Druggability 17, 18
- Dynamic combinatorial library 161–2
- E. coli* 144
- Electrospray ionization mass spectrometry
 (ESI-MS) 68–9, 169–73
 carbionic anhydrase site screening 178–83
 and noncovalent interactions 171–3
 sample preparation 173
- Evotec database 41, 45, 49–9
- EXPRESS-Pick database 227–8
- Fatty acid binding proteins (FABP) 84
- FFSM (fast frequent subgraph mining)
 204
- Fingerprints 5
- FKBP-12 109–10
- Fluorescent screening 20
- Flux analysis 28
- Forsen–Hoffmann experiment 74
- Forward chemical genomics 18–19
- Fourier transform mass spectrometry (FTMS)
 173–7, 174, 177
- Fragment-based drug discovery (FBDD),
 process overview 16
 phase I 17–19
 phase II 22–5
 phase III 26–30
- Fragment capture
 covalent 252–3
 irreversible 253–4
 outlook 255–6
 principles 246–7
 reversible, tethering 247–51
 using metal chelation 253
- Fragment, definition 40
- Fragment libraries 3, 39–43,
 224
 ActiveSight 41, 224–5, 224,
 226–7
 advantages 39–40
 analogues 71
 assembly process 51
 ATLAS 230
 ChemBridge 224, 227–8
 comparison 41
 compound optimisation 47–9
 design 22
 direct combinatorial libraries (DCL)
 167–9
 Evotec 55–9
 extensions and modifications
 54–5
 filters 52–3
 focused sets 46
 IC93 204–5
 Maybridge 212, 213, 224
 molecule selection 43–9
 molecule sources 44
 NMR-based 49–55
 for NMR-based screening
 70–2
 Optiverse 212, 213
 physical properties 44–5
 sampling efficiency 42
 SHAPES 3–4, 47, 71
 size 10, 42–3
 for TINS 137
 toxicity 52
 virtual design tools 236–41
- Fragment optimization, BACE inhibitors,
 isocytosine series 270–1

- Fragments
 - advantages 6–10
 - applications 10–11
 - building blocks 207–9
 - definition 2–6, 15
 - drug- and lead-likeness 50–1
 - evaluation 26–7
 - fusion and growth 8
 - linking 8
 - optimization 28–30
 - selection 43–9
 - substructures 206–7
- Fragment screening 1–2
 - advantages 99–100
 - assay techniques 43
 - carbionic anhydride site, via ESI-FTMS 178–83
 - methods 16, 19–20, 21
 - primary screening 67–8
 - and reactivity 47
 - techniques
 - biochemical assays 69–70
 - choice 70
 - NMR, *see* NMR
 - surface plasmon resonance (SPR) 69
 - X-ray crystallography 11, 70
- Frequent subgraph mining 201–6
 - algorithms
 - FFSM 204
 - Gaston 204
 - MoFa 203–4
 - compared 204–5, **205**
 - example 202–3, 203
 - process overview 202–3
- FTMS 173–7, 174
- Gaston (Graph/Sequence/Tree extractiON)
 - algorithm 204
- GLARE algorithm 237
- GOLD software 45, 230
- GPCRs 147
- G-protein-coupled receptors (GPCR) 248–9
- Graffinity **41**
- Graph theory 200, 201
- GSK **41**
- GSpan algorithm 204, 205
- Heavy atom count (HAC) 230
- Highest-scoring common substructure (HSCS) 214
- High-performance liquid chromatography (HPLC) 188–9
- High-throughput screening (HTS)
 - disadvantages 1–2
 - filters 56–7
 - quality control 57–8
- Hit follow-up 27
- Hit-to-lead strategies **25**
- Hit optimization, BACE inhibitors 268–70
- Hit rate, HTS 2
- HIV integrase 17
- HTFS
 - Evotec library 55–9
 - filters 55–6
 - solubility 56
- Huisgen reaction 164–5
- Hydrazone exchange reaction 163–4, 163
- Hydrogen bond acceptor (HBA), distributions in databases 226
- IC93 database 204–5
- Imines 252–3
- In situ* processes
 - DCC, and mass spectrometry 177–86
 - practical considerations 166–9
- Interleukin-2 248, 249
- Inverse SAR 26
- Isentress 17
- Isocytosines 270–3
- Isothermal titration calorimetry 24
- Kinase inhibitors 125
- Lead-like compounds 2
 - BACE 263–4
 - mFABP 104
 - NOE 103–7
- LFA-1 104–7
- Libraries, *see* fragment libraries
- Ligand efficiency 1, 7, 9
 - BACE 268–70
 - calculation 229–30
 - definition 64
 - efficiency 26–7
- Limit of detection (LOD), ESI-MS 173
- Lipinski ‘rule-of-five’ 64
- MALDI (Matrix-assisted laser desorption/ionization) mass spectrometry 186–7
- Market Basket Analysis 211

- Mass analyser, Fourier transform mass spectrometry (FTMS) 173–7, 174
- Mass-to-charge ratio 175
- Mass spectrometry 20, **21**, 23
and click chemistry 186–90
DIOS 186–7
electrospray ionization MS 68–9, 169–73
examples 178–86
Fourier transform MS 173–7
MALDI 186–7
overview 159–60
spectral deconvolution 170–1
and tethering 247–8
- Maybridge fragment library 212, 213, 224
- MDL Drug Data Report database 214
- Medicinal chemistry, overview 165, **166**
- Membranes 91–2, 144–5
bacterial 151–2
- Merck Molecular Force Field (MMFF) 233
- Metallo- β -lactamase 182–5, 185
- MFABP 104
- Micelles 145–6
- Microfluidic devices 190–3
- MoFa 203–4
- Molecular descriptors 45–6
- Molecular weight 52
CA II-bound ligands **182**
HTS filters 56–7
- Molecule evaluator 220
- Molecule sources 44
- Molfea algorithm 206
- Multitarget drugs 91–2
- Mutagenicity database 215–18
- NMR 11, **21**, 63–5
buffer 72
case studies 83
A-FABP 84–8
Ser/thr kinase 88–9
competition experiments 82
compared with biochemical assays 64
fluorine relaxation filter 79
fragment library 49–55
fragment screening 20
ligand-detected 73–9
strategy 65–7
techniques 73–83, **73**
future applications 91–2
instrument choice 72
line broadening 77–8
primary screening 67–8
problematic targets 89–91
protein characterisation 72–3
protein-detected techniques 79–80
saturation transfer difference (STD) 74–6, 81, 90
SeeDs 5
spin–spin relaxation 77
spy molecule 81
technique choice 80–2
WaterLOGSY 74, 76–7, 81, 263, 264
see also TINS
- NOE matching 100
applications 108–15
applied to lead-like compounds bound to small proteins 103–7
fragments bound to large proteins 123
overview 101–3, 101
pose generation and scoring 107–8
without target 115–19
pose scoring 129
proteins, large 124–8
- Nuclear magnetic resonance (NMR) spectroscopy, *see* NMR
- Nuclear Overhauser effect, *see* NOE
- Optiverse library 212, 213
- Paramagnetic spin labels 78–9
- ParMol 206
- PDF 111–12, 112–14
- Peptides 251–2
- Physical property filters 44–5
Pichia pastoris 145
- Plexxicon 5, **41**
- Polar surface area (PSA), distributions in databases 225
- Poser* algorithm 107–8, **108**, 110, 111
- Potency 9
- Primary screening 67–8
- Process design, overview 15–16
- Progressive catabolism 29–30
- Protein-detected techniques 79–80
- Proteins
bound to fragments, NOE 123–4
capture, reversible, tethering 247–8
characterisation, via NMR 72–3
forming large multimeres 89–91
mass spectra 169–71

- membrane 91–2, 144–154
- stability measurements 24
- target dossier 19
- PubChem 199
- Purchasing 57–8
- Quality control 57–8
- Reactive chemistry, elimination 52
- Reactivity, and fragment screening 47
- Real world, chemical space 44
- RECAP 28
- Receptor matching 9–10
- Reduced complexity screening (RCS) 47–9
- Retrosynthetic Combinatorial Analysis
 - Procedure (RECAP) 47
- Roche 41
- Rule-of-five 64
- Rule-of-three compounds 40
- Sample preparation, electrospray ionization
 - mass spectrometry (ESI-MS) 173
- Saturation transfer difference (STD) 74–6, 81, 90
- Scaffold-based Classification Approach 213
- Scaffold, definition 228–9
- Screen confirmation 25
- Screening libraries, *see* fragment libraries
- Screening techniques 21
 - biochemical and biophysical 20, 22–5
 - in situ* approaches 167
 - NMR 263–5
 - TINS 136, 141–54
 - see also* NMR
 - X-ray crystallography 11, 21, 24, 70, 178
- SeeDs 4–5
- Selected ion monitoring mass spectrometry
 - (SIM-MS) 188
- Self-assembly 67
- Sepaharose 139
- SGX library 3
- SGX Pharmaceuticals 48
- SHAPES library 3–4, 47, 71
- SHIFTX 113
- Similog keys 4, 46
- SLAPSTIC 78–9
- Solubility 52–3
 - HTFS filters 56
- Solvent, and saturation transfer difference 75
- Spin–lattice relaxation 78
- Spin–spin relaxation, and NMR 77
- SPR spectroscopy 21, 23–4, 69, 265–7, 266
- STD (saturation transfer difference) 74–6, 81, 90
- Structure–activity relationships 53
- Subgraph mining, *see* frequent subgraph mining
- Substructure filters 44–5
- Substructure mining 206–7
 - algorithms 205
 - building blocks 207–9, 208
- Surface plasmon resonance (SPR) spectroscopy 21, 23–4, 69, 265–7, 266
- Surrogate compounds 19
- Synthon 237
- Synthon Analysis 237–8
- Tangible world 44
- Target assessment 17–19
- Target-guided *in situ* medicinal chemistry 160–1
- Target-immobilized NMR screening, *see* TINS
- Tethering 247–51, 247
 - disulfide tethering and capture 248–50
 - with extenders 250–1
- Thymidylate kinases 29–30
- TINS 136
 - applications 150–4
 - soluble targets 150, 154
 - immobilization 137–41
 - membrane proteins 146–8
 - membrane proteins 144–50, 154
 - membranes 145–6
 - reference proteins 148
 - screening
 - ligands 141–3
 - membrane proteins 148–50
- Toxicity 52, 216
- Vernalis 47
- Virtual fragment screening 228–36
- Virtual Library Tool Kit (VLTK) 237–40
- Virtual retro-synthesis 208–9
- Virtual world 44
- VLTK 240
- Warmr algorithm 206
- WaterLOGSY 74, 76–7, 263, 264
 - for novel targets 81
- WOMBAT (WORld of Molecular BioAcTivity) 199–200
- X-ray crystallography 11, 21, 24, 70, 178

